First Wave will concentrate on advancing a portfolio of gastrointestinal disease therapies, including latiglutenase, which encompasses multiples late-stage clinical assets.

X4 Pharmaceuticals is a biotech company specialized in the development of therapeutic drugs focusing on CXCR4 and immunological biology.

PeptiDream is a biotechnology company based in Japan, focused on the development of innovative macrocyclic peptide drugs.

Novo Nordisk has excelled in research and development, aiding over 40 million chronic disease patients globally.

In the wake of the receding tide of COVID-19 oral medication and vaccines, Pfizer seems to have returned to an awkward predicament where all potential growth points have fallen flat.

Despite Novartis being a consistent top contender in the pharmaceutical sector in terms of revenue, its growth and market value in recent years has been rather dismal.

AstraZeneca has shown a steady performance in the past two years, and its market value has effectively stabilized at over 200 billion.

The Swiss pharmaceutical giant Roche has seen sluggish growth in its oncology division, with almost no increase in four years, worsened further by the weakening of the diagnostic division due to the COVID-19 pandemic.

Since acquiring Allergan, AbbVie has experienced a period of stable performance, but this year has seen a significant decline in the performance of its two heavyweight drugs, Adalimumab and Ibrutinib.

Merck's recent revenue performance remains steady, with the K drug continuing to grow and earning the title of "New Generation Drug King".

Novo Nordisk has nearly succeeded by relying on one metabolic domain and leveraging the power of GLP-1 alone, raising its market value from 100 billion to over 400 billion, reaching unprecedented heights on the centenary of its founding.

The performance of Johnson & Johnson's pharmaceutical sector is quite robust among large pharmaceutical companies, with the driving force of the two major engines - Ustekinumab and Daratumumab - being very adequate.